Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00174824 · ClinicalTrials.gov registry record · Phase 4
Comparison of Insulin Glargine and NPH Human Insulin in Progression of Diabetic Retinopathy in Type 2 Diabetic Patients
A Phase 4 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,024
- Enrollment target
NCT00174824 is a Phase 4 study that has completed, run by Sanofi. The registered enrollment target is 1,024 participants.
The verdict
NCT00174824, a Phase 4 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,024 participants
- Enrollment target
Study Summary
To compare the progression of diabetic retinopathy in type 2 diabetic patients with mild-to-moderate diabetic retinopathy treated with insulin glargine vs NPH human insulin.
Interventions
- DRUG Insulin glargine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,024 participants |
| Start Date | 2001-06 |
| Est. Completion | 2007-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00174824
The ClinicalTrials.gov registry entry for NCT00174824 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 1,024 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Insulin glargine is the first listed.
NCT00174824 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00174824 about?
NCT00174824 is a clinical study titled "Comparison of Insulin Glargine and NPH Human Insulin in Progression of Diabetic Retinopathy in Type 2 Diabetic Patients". To compare the progression of diabetic retinopathy in type 2 diabetic patients with mild-to-moderate diabetic retinopathy treated with insulin glargine vs NPH human insulin.
What is the current status of trial NCT00174824?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,024 participants. The study started on 2001-06. Estimated completion is 2007-04.
What interventions are being tested in trial NCT00174824?
The interventions under investigation include: Insulin glargine (DRUG).
Who is sponsoring clinical trial NCT00174824?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.